{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:32:43Z","timestamp":1761507163639,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jamda.2021.01.063","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:29:28Z","timestamp":1613564968000},"page":"2190-2195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation"],"prefix":"10.1016","volume":"22","author":[{"given":"Mar\u00eda","family":"Cesp\u00f3n-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Raposeiras-Roub\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Abu-Assi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Melendo-Viu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Garc\u00eda-Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"\u00cd\u00f1iguez-Romo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2021.01.063_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eur002","article-title":"Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: Primary prevention","volume":"13","author":"Savelieva","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jamda.2021.01.063_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.116.023163","article-title":"Modifiable risk factors and atrial fibrillation","volume":"136","author":"Lau","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2021.01.063_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944708092111","article-title":"Atrial fibrillation and renin-angiotensin system","volume":"2","author":"Serra","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.jamda.2021.01.063_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jacc.2019.11.013","article-title":"Atrial failure as a clinical entity: JACC review topic of the week","volume":"75","author":"Bisbal","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2021.01.063_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2021.01.063_bib6","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2021.01.063_bib7","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jamda.2021.01.063_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jamda.2021.01.063_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2004.06.080","article-title":"Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2021.01.063_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2021.01.063_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2796.2007.01780.x","article-title":"Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation","volume":"261","author":"Lip","year":"2007","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jamda.2021.01.063_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.recesp.2019.10.022","article-title":"Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry","volume":"73","author":"Cobas Paz","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jamda.2021.01.063_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2021.01.063_bib14","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"G\u00f3mez-Outes","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2021.01.063_bib15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","article-title":"Antihypertensive treatment and risk of atrial fibrillation: A nationwide study","volume":"35","author":"Marott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jamda.2021.01.063_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.recesp.2019.02.017","article-title":"Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction","volume":"73","author":"Raposeiras-Roub\u00edn","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jamda.2021.01.063_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jamda.2014.08.005","article-title":"Atrial fibrillation is associated with impaired mobility in community-dwelling older adults","volume":"15","author":"Donoghue","year":"2014","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2021.01.063_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/europace\/euq439","article-title":"Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study)","volume":"13","author":"Yamashita","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jamda.2021.01.063_bib19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","article-title":"Valsartan for prevention of recurrent atrial fibrillation","volume":"360","author":"Disertori","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2021.01.063_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM198709103171104","article-title":"The natural history of lone atrial fibrillation. A population-based study over three decades","volume":"317","author":"Kopecky","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2021.01.063_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2021.01.063_bib22","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861021001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861021001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:27:51Z","timestamp":1761506871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861021001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1525861021001134"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2021.01.063","relation":{},"ISSN":["1525-8610"],"issn-type":[{"type":"print","value":"1525-8610"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2021.01.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.","name":"copyright","label":"Copyright"}]}}